TLDR:
Key Points:
- CAR-T industry has raised over $128.25 billion through various funding deals
- 170 companies worldwide are developing CAR-T products and therapies
In recent years, the CAR-T industry has seen a surge in funding, with over $128.25 billion raised through various deals. This includes 59 licensing deals, 65 collaboration deals, and 11 M&A deals whose values were not disclosed. The total value, if estimated for undisclosed deals, would be around $240 billion. With the introduction of therapies like Kymriah and Yescarta, funding for CAR-T companies has increased significantly.
There are over 170 companies globally working on CAR-T therapies, with nearly 970 early and late-stage therapies in development. These companies have also entered into 98 collaboration deals, totaling $21.7 billion in disclosed transactions. Additionally, venture capital investments worth $6.7 billion and IPO funding of $5.8 billion have enabled CAR-T companies to expand their technology platforms and clinical trial programs.
With 417,801 patent records and 4,024 granted patents, large pharmaceutical companies are entering the CAR-T field through licensing deals, amounting to $3.9 billion. M&A deals in the CAR-T industry make up the largest financial percentage, totaling $95.9 billion over the past decade.
Currently, six CAR-T therapies have been approved by the U.S. FDA, leading to commercialization in various regions globally. Over 706 CAR-T programs are in clinical development, showing the rapid growth of the sector. This report provides insight into the different types of investments in the CAR-T industry and profiles 78 leading competitors involved in funding events.
This article highlights the significant amount of funding flowing into the CAR-T industry, propelling its growth and development in the healthcare market worldwide.
